Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGB | P11216 | 3/20 | 0.41 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.40 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.40 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.40 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | OGA | O60502 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | TYR | P14679 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14783108 | 0.88 | PRKD3 (0.40) | GAA | |
| SCHEMBL14783109 | 0.88 | PRKD3 (0.40) | GAA | |
| SCHEMBL26304331 | 0.85 | LGALS1 (0.42) | PYGBLGALS1LGALS3LGALS9LGALS8 | |
| SCHEMBL18884178 | 0.85 | LGALS1 (0.42) | PYGBLGALS1LGALS3LGALS9LGALS8 | |
| SCHEMBL21391580 | 0.85 | LGALS1 (0.42) | PYGBLGALS1LGALS3LGALS9LGALS8 | |
| SCHEMBL24443605 | 0.85 | LGALS1 (0.42) | PYGBLGALS1LGALS3LGALS9LGALS8 | |
| SCHEMBL12672708 | 0.85 | LGALS1 (0.42) | PYGBLGALS1LGALS3LGALS9LGALS8 | |
| SCHEMBL23030291 | 0.85 | PYGB (0.35) | PYGBLGALS1LGALS3LGALS9LGALS8 | |
| SCHEMBL18022194 | 0.83 | LGALS1 (0.38) | PYGBLGALS1LGALS3LGALS9LGALS8 | |
| SCHEMBL28578027 | 0.82 | OGA (0.43) | PYGBLGALS1LGALS3LGALS9LGALS8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11540539-B2 | Reduced sodium food products | GENERAL MILLS, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-20220047725-A1 | CHEMILUMINESCENT PROBES FOR DIAGNOSTICS AND IN VIVO IMAGING | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2022-02-17 | — | — | US | disclosed |
| US-10570104-B2 | Metabolically programmed metal chelators and uses thereof | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2020-02-25 | — | — | US | disclosed |
| US-10010535-B2 | Desferrithiocin analogs and uses thereof | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2018-07-03 | — | — | US | disclosed |
| US-20180140581-A1 | METABOLICALLY PROGRAMMED METAL CHELATORS AND USES THEREOF | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10570104-B2 | Metabolically programmed metal chelators and uses thereof | FECH, SLC19A1, SLC40A1 | PYGB 444/4885LGALS1 3977/4885LGALS3 4453/4885 |
| US-20180140581-A1 | METABOLICALLY PROGRAMMED METAL CHELATORS AND USES THEREOF | FECH, SLC19A1, SLC40A1 | PYGB 444/4885LGALS1 3977/4885LGALS3 4453/4885 |
| US-20220047725-A1 | CHEMILUMINESCENT PROBES FOR DIAGNOSTICS AND IN VIVO IMAGING | DAXX, DCAF15, CDY1; CDY1B | PYGB 996/4885LGALS1 273/4885LGALS3 147/4885 |
| US-10010535-B2 | Desferrithiocin analogs and uses thereof | FECH, TFRC, FTH1 | PYGB 1233/4885LGALS1 2325/4885LGALS3 2758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.